热门
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
文献类型：期刊论文
| 作者 | Bergethon, K; Shaw, AT; Ou, SHI; Katayama, R; Lovly, CM; McDonald, NT; Massion, PP; Siwak-Tapp, C; Gonzalez, A; Fang, R |
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2012 |
| 卷号 | 30期号:8页码:863-870 |
| 通讯作者 | Iafrate, AJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.,aiafrate@partners.org |
| 英文摘要 | Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs). Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement. Patients and Methods Using a ROS1 fluorescent in situ hybridization (FISH) assay, we screened 1,073 patients with NSCLC and correlated ROS1 rearrangement status with clinical characteristics, overall survival, and when available, ALK rearrangement status. In vitro studies assessed the responsiveness of cells with ROS1 rearrangement to the tyrosine kinase inhibitor crizotinib. The clinical response of one patient with ROS1-rearranged NSCLC to crizotinib was investigated as part of an expanded phase I cohort. Results Of 1,073 tumors screened, 18 (1.7%) were ROS1 rearranged by FISH, and 31 (2.9%) were ALK rearranged. Compared with the ROS1-negative group, patients with ROS1 rearrangements were significantly younger and more likely to be never-smokers (each P < .001). All of the ROS1-positive tumors were adenocarcinomas, with a tendency toward higher grade. ROS1-positive and-negative groups showed no difference in overall survival. The HCC78 ROS1-rearranged NSCLC cell line and 293 cells transfected with CD74-ROS1 showed evidence of sensitivity to crizotinib. The patient treated with crizotinib showed tumor shrinkage, with a near complete response. Conclusion ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib shows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC. J Clin Oncol 30: 863-870. (C) 2012 by American Society of Clinical Oncology |
| 学科主题 | Oncology |
| 类目[WOS] | Oncology |
| 关键词[WOS] | ANAPLASTIC LYMPHOMA KINASE ; FUSION ; GLIOBLASTOMA ; GEFITINIB ; EML4-ALK ; MUTATIONS ; TUMORS ; GENE ; INHIBITORS ; FEATURES |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000302626600023 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/633]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Bergethon, K,Shaw, AT,Ou, SHI,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,30(8):863-870. |
| APA | Bergethon, K.,Shaw, AT.,Ou, SHI.,Katayama, R.,Lovly, CM.,...&Iafrate, AJ.(2012).ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.JOURNAL OF CLINICAL ONCOLOGY,30(8),863-870. |
| MLA | Bergethon, K,et al."ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers".JOURNAL OF CLINICAL ONCOLOGY 30.8(2012):863-870. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。